Tam Tran - Concepedia

Author

Tam Tran

Bristol-Myers Squibb (Switzerland)

Also Known As

T. S. TRAN, Tam Tran

Publications

879

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (Switzerland)

About

Tam Tran is an author at Bristol-Myers Squibb (Switzerland) specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	819
2	Cell Biology	4	4	800
3	Molecular Biology	2	2	689
4	Natural Sciences	1	1	628
5	Biochemistry	1	1	52

Tam Tran

Publications

871

Citations

H-Index

Page 1

	Year	Citations
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase Mary E. Matyskiela, Gang Lu, Takumi Ito, Nature Protein FunctionSignal TransductionCell RegulationCrl4crbn Ubiquitin LigaseNatural Sciences	2016	628
CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth <i>in vitro</i> Toshiya Tsuji, Lisa M. Sapinoso, Tam Tran, Oncotarget Dual InhibitorDna DamageMolecular BiologyCell DeathDna-dependent Protein Kinase	2017	61
The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen Jennifer R. Riggs, Mark A. Nagy, Jan Elsner, Journal of Medicinal Chemistry Breast OncologyPharmaceutical ChemistryTumor BiologyMedicinal ChemistryOncology	2017	59
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: <i>In Vitro</i> and <i>In Vivo</i> Characterization Deborah S. Mortensen, Kimberly E. Fultz, Shuichan Xu, Molecular Cancer Therapeutics Cancer BiologyMtorc1 ComplexTumor BiologyMolecular PharmacologySignaling Pathway	2015	52
Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint Dan Zhu, Shuichan Xu, Gordafaried Deyanat‐Yazdi, Molecular Cancer Therapeutics	2018	35
Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors Garrick K. Packard, Patrick Papa, Jennifer R. Riggs, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryMedicinal ChemistryB-raf InhibitorsMedicineRational Drug Design	2011	19
Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy Jennifer R. Riggs, Jan Elsner, Dan Cashion, Journal of Medicinal Chemistry	2019	17

Page 1